Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=3&sort=-keywords
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-keywords", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-keywords", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=4&sort=-keywords", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=-keywords" }, "data": [ { "type": "Grant", "id": "7686", "attributes": { "award_id": "75N91019D00024-0-759102000011-1", "title": "NIAID BIG EFFECT TRIAL (BET) FOR COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-05-01", "end_date": "2022-04-30", "award_amount": 25810387, "principal_investigator": { "id": 23486, "first_name": "BETH", "last_name": "BASELER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the Big Effect Trial (BET) to evaluate therapeutic agents against COVID-19.", "keywords": [ "COVID-19", "National Institute of Allergy and Infectious Disease", "Therapeutic Agents", "therapeutic evaluation" ], "approved": true } }, { "type": "Grant", "id": "8819", "attributes": { "award_id": "75N93021C00028-0-9999-1", "title": "INTEGRATED ANALYSIS OF HETEROGENEOUS COVID-19 DATASETS USING KNOWLEDGE GRAPH.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-01", "end_date": "2022-08-31", "award_amount": 300000, "principal_investigator": { "id": 24620, "first_name": "FRANK", "last_name": "MANION", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1763, "ror": "", "name": "MELAX TECHNOLOGIES, INC.", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1763, "ror": "", "name": "MELAX TECHNOLOGIES, INC.", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of this study is to construct COVID-19 Dataset Knowledge Graph (COVID-DKG) and to demonstrate its uses in COVID-19 research and development.", "keywords": [ "COVID-19", "Data Set", "Goals", "Small Business Innovation Research Grant", "coronavirus disease", "knowledge graph", "research and development" ], "approved": true } }, { "type": "Grant", "id": "9164", "attributes": { "award_id": "75N91019D00024-0-759102000003-45", "title": "NIH Project 5 COVID-19 Data Hub - CDEs and Common Data Model", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-08-31", "end_date": "2021-08-30", "award_amount": 150000, "principal_investigator": { "id": 24928, "first_name": "LEONARD", "last_name": "FREEDMAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Office of Data Science Strategy (ODSS) agrees to provide $150,000.00 to the National Cancer Institute to support NIH Project 5 COVID-19 Data Hub - CDEs and Common Data Model.", "keywords": [ "COVID-19", "Data Science", "National Cancer Institute", "United States National Institutes of Health", "data hub", "data modeling" ], "approved": true } }, { "type": "Grant", "id": "9363", "attributes": { "award_id": "1S10AI162059-01", "title": "Personal Protective Equipment for Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6245, "first_name": "Philip O.", "last_name": "Renzullo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-11-05", "end_date": "2022-10-31", "award_amount": 21360749, "principal_investigator": { "id": 6247, "first_name": "Lawrence", "last_name": "Corey", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 757, "ror": "", "name": "FRED HUTCHINSON CANCER RESEARCH CENTER", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 757, "ror": "", "name": "FRED HUTCHINSON CANCER RESEARCH CENTER", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Planned COVID-19 vaccine trials require screening, enrolling, and following over 150,000 volunteer study participants over 24 months. The trial participants will be selected based on their risk of COVID-19 infection, with trial participants coming from settings with high rates of community transmission, groups with higher risk of progression to symptomatic disease, or both. Study staff working on COVID-19 vaccine trials will need to interact with trial participants during regular visits as well as conducting in-person assessments of all vaccine trial participants with symptoms that could be due to COVID-19 disease. This will result in close contact between study staff and high-risk participants or infected participants. As a result, study staff need to access a regular supply of personal protective equipment (PPE), including surgical masks, face shields or goggles, gowns, and disposable gloves, as well as the ability to sanitize hands frequently. This combination of PPE will be used during all risky interactions with study participants, such as during nasal swab collection and during evaluation of participants for possible study endpoints, including symptomatic COVID-19 disease. In addition, all staff will need to wear surgical face masks during and throughout their normal workday in the health care setting or on site for mobile study satellite sites. Without appropriate PPE, health care workers are vulnerable to infection with COVID-19, as well as passively transmitting to persons with whom they are in close physical contact. Access to adequate PPE is a critical component of the safe and effective conduct of COVID-19 vaccine trials, and will enable accurate determination of the study endpoints, especially symptomatic COVID- 19 disease.", "keywords": [ "COVID-19", "COVID-19 vaccine", "Clinical Research", "Clinical Treatment", "Clinical Trials", "Collection", "Communities", "Disease", "Enrollment", "Evaluation", "Face", "Goggles", "Hand", "Health Personnel", "Infection", "Participant", "Persons", "Resources", "Risk", "SARS-CoV-2 infection", "Site", "Symptoms", "Vaccines", "Visit", "base", "health care settings", "high risk", "nasal swab", "personal protective equipment", "screening", "surgical mask", "symptomatic COVID-19", "transmission process", "vaccine trial", "volunteer" ], "approved": true } }, { "type": "Grant", "id": "6403", "attributes": { "award_id": "1S10AI160636-01", "title": "Personal Protective Equipment for Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 21534, "first_name": "Philip O.", "last_name": "Renzullo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-08-25", "end_date": "2022-07-31", "award_amount": 24903100, "principal_investigator": { "id": 21535, "first_name": "Lawrence", "last_name": "Corey", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 757, "ror": "", "name": "FRED HUTCHINSON CANCER RESEARCH CENTER", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Planned COVID-19 vaccine trials require screening, enrolling, and following over 150,000 volunteer study participants over 24 months. The trial participants will be selected based on their risk of COVID-19 infection, with trial participants coming from settings with high rates of community transmission, groups with higher risk of progression to symptomatic disease, or both. Study staff working on COVID-19 vaccine trials will need to interact with trial participants during regular visits as well as conducting in-person assessments of all vaccine trial participants with symptoms that could be due to COVID-19 disease. This will result in close contact between study staff and high-risk participants or infected participants. As a result, study staff need to access a regular supply of personal protective equipment (PPE), including surgical masks, face shields or goggles, gowns, and disposable gloves, as well as the ability to sanitize hands frequently. This combination of PPE will be used during all risky interactions with study participants, such as during nasal swab collection and during evaluation of participants for possible study endpoints, including symptomatic COVID-19 disease. In addition, all staff will need to wear surgical face masks during and throughout their normal workday in the health care setting or on site for mobile study satellite sites. Without appropriate PPE, health care workers are vulnerable to infection with COVID-19, as well as passively transmitting to persons with whom they are in close physical contact. Access to adequate PPE is a critical component of the safe and effective conduct of COVID-19 vaccine trials, and will enable accurate determination of the study endpoints, especially symptomatic COVID- 19 disease.", "keywords": [ "COVID-19", "COVID-19 vaccine", "Clinical Research", "Clinical Treatment", "Clinical Trials", "Collection", "Communities", "Disease", "Enrollment", "Equipment", "Evaluation", "Face", "Goggles", "Hand", "Health Personnel", "Infection", "Masks", "Nose", "Operative Surgical Procedures", "Participant", "Persons", "Resources", "Risk", "Site", "Swab", "Symptoms", "Vaccines", "Visit", "base", "face mask", "health care settings", "high risk", "screening", "transmission process", "vaccine trial", "volunteer" ], "approved": true } }, { "type": "Grant", "id": "9039", "attributes": { "award_id": "75N91019D00024-P00002-759102000011-1", "title": "NIAID BIG EFFECT TRIAL (BET) FOR COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-05-01", "end_date": "2022-04-30", "award_amount": 24161705, "principal_investigator": { "id": 23486, "first_name": "BETH", "last_name": "BASELER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the Big Effect Trial (BET) to evaluate therapeutic agents against COVID-19.", "keywords": [ "COVID-19", "COVID-19 therapeutics", "Coronavirus", "National Institute of Allergy and Infectious Disease", "Therapeutic Agents", "therapeutic evaluation" ], "approved": true } }, { "type": "Grant", "id": "10700", "attributes": { "award_id": "75N93021D00035-0-759302200002-1", "title": "Completion of ACTIV-2 Study", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-11-06", "end_date": "2024-10-31", "award_amount": 82531927, "principal_investigator": { "id": 26756, "first_name": "ANGEE", "last_name": "GREER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1807, "ror": "", "name": "PPD, INC.", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "NIAID is sponsoring a clinical research study on novel therapeutics for COVID-19, which is one of the clinical studies for Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV). With an existing clinical trial infrastructure and multiple support contracts to provide services related to clinical trials support, regulatory support and pharmacy support, NIAID serves as the sponsor for the COVID-19 clinical trial entitled “A5401: Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)” also known as ACTIV-2. The objective of ACTIV-2 is to evaluate the safety and efficacy of multiple investigational agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly enhancing viral control in order to limit disease progression.", "keywords": [ "COVID-19", "COVID-19 therapeutics", "Clinical Research", "Clinical Trials", "Disease Progression", "Immune response", "Infrastructure", "Investigation", "National Institute of Allergy and Infectious Disease", "Outpatients", "Pharmacy facility", "Reporting", "SARS-CoV-2 infection", "Safety", "Services", "Support Contracts", "Therapeutic Intervention", "Viral", "coronavirus disease", "novel therapeutics", "research study", "therapeutic vaccine", "treatment trial" ], "approved": true } }, { "type": "Grant", "id": "12214", "attributes": { "award_id": "1UC7AI180314-01", "title": "Resources and Workforce Development for the Tulane Regional Biocontainment Laboratory", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 27982, "first_name": "FAYNA C", "last_name": "Diaz San Segundo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-22", "end_date": "2028-07-31", "award_amount": 2878190, "principal_investigator": { "id": 6569, "first_name": "JAY", "last_name": "RAPPAPORT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 811, "ror": "", "name": "TULANE UNIVERSITY OF LOUISIANA", "address": "", "city": "", "state": "LA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 811, "ror": "", "name": "TULANE UNIVERSITY OF LOUISIANA", "address": "", "city": "", "state": "LA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Tulane National Primate Research Center (TNPRC) is one of seven National Primate Research Centers (NPRCs) dedicated to conducting nonhuman primate (NHP) research with the goal of improving human health. With a primary focus on infectious disease and biodefense research, the TNPRC is only NPRC with a Regional Biocontainment Laboratory (RBL) at Biosafety Level 3 (BSL-3) for the study of high-consequence pathogens, including select agents and toxins. The Tulane University RBL, which came online in June 2010, has been critical for advancing research at the TNPRC and across the region on biodefense agents and emerging infectious diseases, with a primary focus on in vivo studies using NHPs. Since its inception, significant infrastructure projects have been completed to capitalize on the presence of the RBL and grow and diversify research at the TNPRC. In recent years, and particularly with the onset of the COVID-19 pandemic, the TNPRC RBL has expanded its capabilities and capacity to accommodate BSL-3-level emerging pathogen and biodefense research. The overarching goal of the proposed project is to strategically enhance and fortify BSL-3 research capabilities within the TNPRC RBL to ensure the long-term success of this program in support of infectious disease and biodefense research and countermeasure development. This will be accomplished through the following Specific Aims: (1) Ensure agility of the TNPRC RBL response to emerging public health concerns and threats by leveraging the robust research infrastructure and unique research strengths of the TNPRC and implementing exceptional preventative maintenance processes that allow for best practices, quality control, and extensive safety oversight for work with high- consequence pathogens. (2) Provide formal structure for sharing of best practices for safety, research procedures and facilities management with partners and other RBLs. (3) Coordinate practices and procedures across the Biodefense Facilities Network to leverage the strengths of all 12 RBLs; ensure efficient and effective cross-training and sharing of methodologies, SOPs, and best practices; and coordinate and advance infectious disease and biodefense research and countermeasure development nation-wide.", "keywords": [ "COVID-19", "COVID-19 pandemic", "Communicable Diseases", "Dedications", "Development", "Emerging Communicable Diseases", "Ensure", "Equipment", "Funding", "Goals", "Grant", "Health", "Human", "Infrastructure", "Laboratories", "Maintenance", "Methodology", "National Institute of Allergy and Infectious Disease", "Operative Surgical Procedures", "Primates", "Procedures", "Process", "Public Health", "Quality Control", "Research", "Research Infrastructure", "Resource Development", "Safety", "Structure", "Toxin", "Training", "United States National Institutes of Health", "Universities", "Work", "Workforce Development", "animal colony", "base", "biodefense", "biosafety level 3 facility", "emerging pathogen", "fortification", "germ free condition", "improved", "in vivo", "medical countermeasure", "nonhuman primate", "operation", "pandemic preparedness", "pandemic response", "pathogen", "programs", "response", "safety practice", "success" ], "approved": true } }, { "type": "Grant", "id": "6496", "attributes": { "award_id": "3U45ES006175-31S1", "title": "Training At-Risk Workers on the Corona Virus and Bio Safety Hazards", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Environmental Health Sciences (NIEHS)" ], "program_reference_codes": [], "program_officials": [ { "id": 21786, "first_name": "James W", "last_name": "Remington", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1992-09-01", "end_date": "2022-05-31", "award_amount": 250000, "principal_investigator": { "id": 21787, "first_name": "Ashlee", "last_name": "Fitch", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1044, "ror": "", "name": "STEELWORKER CHARITABLE/EDUCATIONAL ORG", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "In response to the COVID-19 pandemic that has swept the country, the USW Tony Mazzocchi Center and its training partners will use their decades of experience in health and safety training including infectious disease to provide information and support to workers and community members. The program is designed to provide information on disease transmission and controls necessary to reduce its impact. Additionally, because physical distancing has become part of the “new normal”, this program will include support for each of the training partners to equip themselves to conduct training using both online and blended formats. These modalities differ from the face to face training typically conducted under our programs. The change in approach will require both technological upgrades and a new way of sharing material. The three parts of this program include: Training and Outreach: -Produce and conduct web-based training on COVID-19 and its effect on workplaces and communities -Produce and conduct Spanish language trainings on COVID-19 Developing and Deploying Advanced Technology: -Support online training platforms for the TMC and its training partners -Purchase of software or licenses -Purchase of training tools that support distance learning Strengthening the Special Emergency Response Training (SERTs) Program: -Onboarding four additional worker trainers to the SERTs team -Initial training on relevant topics concerning HAZWOPER and COVID-19.", "keywords": [ "COVID-19", "COVID-19 pandemic", "Communicable Diseases", "Communities", "Computer software", "Coronavirus", "Country", "Distance Learning", "E-learning", "Education and Outreach", "Emergency response", "Hazardous Waste Operations and Emergency Response", "Health", "Immigrant", "Institution", "Licensing", "Modality", "Performance", "Risk", "Safety", "Technology", "Training", "Training Programs", "Workplace", "design", "disease transmission", "disorder control", "experience", "hazard", "language training", "member", "pandemic disease", "programs", "response", "support tools" ], "approved": true } }, { "type": "Grant", "id": "6495", "attributes": { "award_id": "3U45ES006175-30S1", "title": "Training At-Risk Workers on the Corona Virus and Bio Safety Hazards", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Environmental Health Sciences (NIEHS)" ], "program_reference_codes": [], "program_officials": [ { "id": 21784, "first_name": "Joseph T", "last_name": "Hughes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-07-02", "end_date": "2021-07-31", "award_amount": 90292, "principal_investigator": { "id": 21785, "first_name": "Ashlee", "last_name": "Fitch", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1044, "ror": "", "name": "STEELWORKER CHARITABLE/EDUCATIONAL ORG", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "In response to the COVID-19 pandemic that has swept the country, the USW Tony Mazzocchi Center and its training partners will use their decades of experience in health and safety training including infectious disease to provide information and support to workers and community members. The program is designed to provide information on disease transmission and controls necessary to reduce its impact. Additionally, because physical distancing has become part of the “new normal”, this program will include support for each of the training partners to equip themselves to conduct training using both online and blended formats. These modalities differ from the face to face training typically conducted under our programs. The change in approach will require both technological upgrades and a new way of sharing material. The three parts of this program include: Training and Outreach: -Produce and conduct web-based training on COVID-19 and its effect on workplaces and communities -Produce and conduct Spanish language trainings on COVID-19 Developing and Deploying Advanced Technology: -Support online training platforms for the TMC and its training partners -Purchase of software or licenses -Purchase of training tools that support distance learning Strengthening the Special Emergency Response Training (SERTs) Program: -Onboarding four additional worker trainers to the SERTs team -Initial training on relevant topics concerning HAZWOPER and COVID-19", "keywords": [ "COVID-19", "COVID-19 pandemic", "Communicable Diseases", "Communities", "Computer software", "Coronavirus", "Country", "Distance Learning", "E-learning", "Education and Outreach", "Emergency response", "Hazardous Waste Operations and Emergency Response", "Health", "Immigrant", "Institution", "Licensing", "Modality", "Performance", "Risk", "Safety", "Technology", "Training", "Training Programs", "Workplace", "design", "disease transmission", "disorder control", "experience", "hazard", "language training", "member", "pandemic disease", "programs", "response", "support tools" ], "approved": true } } ], "meta": { "pagination": { "page": 3, "pages": 1392, "count": 13920 } } }